{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:06:40Z","timestamp":1784074000129,"version":"3.55.0"},"reference-count":123,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Somatostatin (SRIF) and its receptors (SSTR) are key players in the regulation of neuroendocrine neoplasms (NEN), with significant implications for diagnosis, prognosis, and treatment. The field of SSTR-targeted drugs\/ligands (SRLs) is continuously evolving, with emerging novel therapeutic approaches aiming to address the numerous unmet needs and limitations of the standard-of-care (SOC) SRLs. In the present manuscript, we aim to provide a concise review of the field, focusing on the new and ongoing developments and potential novel approaches to be considered in the future. The paper (1) provides insights into the pathophysiology of SSTR in relation to unmet needs in the SRL efficacy and limitations, (2) presents a state-of-the-art assessment of knowledge on the SOC SRLs, and (3) depicts current ongoing and future research, highlighting areas of insufficient knowledge for SRLs in NEN routine practice.<\/jats:p>","DOI":"10.1210\/endrev\/bnag007","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:44:07Z","timestamp":1774442647000},"page":"496-511","source":"Crossref","is-referenced-by-count":0,"title":["SSTR-based therapies for gastroenteropancreatic and thoracic neuroendocrine neoplasms"],"prefix":"10.1210","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-9154","authenticated-orcid":false,"given":"Simona","family":"Grozinsky-Glasberg","sequence":"first","affiliation":[{"name":"Neuroendocrine Tumor Unit, ENETS Centre of Excellence, Division of Medicine, Hadassah Medical Organization and Faculty of Medicine, the Hebrew University , Jerusalem 91120 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Kos-Kudla","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Neuroendocrine Tumors, ENETS Centre of Excellence, Department of Pathophysiology and Endocrinology, Medical University of Silesia , Katowice 40-514 ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"3","key":"2026071419565646300_bnag007-B1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms","volume":"15","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2026071419565646300_bnag007-B2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ecl.2018.04.010","article-title":"When and how to use somatostatin analogues","volume":"47","author":"de Herder","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2026071419565646300_bnag007-B3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/17446651.2023.2166488","article-title":"Resistance of neuroendocrine tumours to somatostatin analogs","volume":"18","author":"Angelousi","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"16","key":"2026071419565646300_bnag007-B4","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.3390\/ijms20163940","article-title":"Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms","volume":"20","author":"Gatto","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026071419565646300_bnag007-B5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev.me.27.020176.002115","article-title":"Somatostatin: physiological and clinical significance","volume":"27","author":"Guillemin","year":"1976","journal-title":"Annu Rev Med"},{"issue":"1-2","key":"2026071419565646300_bnag007-B6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2007.12.007","article-title":"Pharmacological profile of somatostatin and cortistatin receptors","volume":"286","author":"Siehler","year":"2008","journal-title":"Mol Cell Endocrinol"},{"issue":"1-2","key":"2026071419565646300_bnag007-B7","first-page":"1","article-title":"Somatostatin, cortistatin and their receptors in health and disease. Foreword","volume":"286","author":"Castano","year":"2008","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2026071419565646300_bnag007-B8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol"},{"issue":"7","key":"2026071419565646300_bnag007-B9","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.3390\/ijms21072568","article-title":"Role of somatostatin in the regulation of central and peripheral factors of satiety and obesity","volume":"21","author":"Kumar","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2026071419565646300_bnag007-B10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2982.2008.01088.x","article-title":"Distribution and expression levels of somatostatin and somatostatin receptors in the ileum of normal and acutely schistosoma mansoni-infected SSTR2 knockout\/lacZ knockin mice","volume":"20","author":"Van Op den Bosch","year":"2008","journal-title":"Neurogastroenterol Motil"},{"issue":"4","key":"2026071419565646300_bnag007-B11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International union of basic and clinical pharmacology. CV. somatostatin receptors: structure, function, ligands, and new nomenclature","volume":"70","author":"G\u00fcnther","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"12","key":"2026071419565646300_bnag007-B12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.tips.2013.10.001","article-title":"Illuminating somatostatin analog action at neuroendocrine tumor receptors","volume":"34","author":"Reubi","year":"2013","journal-title":"Trends Pharmacol Sci"},{"issue":"5838","key":"2026071419565646300_bnag007-B13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/294259a0","article-title":"Receptor binding of somatostatin-28 is tissue specific","volume":"294","author":"Srikant","year":"1981","journal-title":"Nature"},{"issue":"2","key":"2026071419565646300_bnag007-B14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0306-4522(86)90158-2","article-title":"Distribution of somatostatin receptors in the human brain: an autoradiographic study","volume":"18","author":"Reubi","year":"1986","journal-title":"Neuroscience"},{"issue":"3","key":"2026071419565646300_bnag007-B15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0165-6147(00)88988-9","article-title":"Classification and nomenclature of somatostatin receptors","volume":"16","author":"Hoyer","year":"1995","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"2026071419565646300_bnag007-B16","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1210\/jc.2008-2564","article-title":"Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors","volume":"94","author":"Duran-Prado","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565646300_bnag007-B17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1749-6632.2011.05985.x","article-title":"Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology","volume":"1220","author":"Cordoba-Chacon","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"2026071419565646300_bnag007-B18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbadis.2017.11.002","article-title":"Characterization of somatostatin receptors and associated signaling pathways in pancreas of R6\/2 transgenic mice","volume":"1864","author":"Somvanshi","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"2026071419565646300_bnag007-B19","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/1878-0261.13107","article-title":"Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST(5)) in pituitary and pancreatic neuroendocrine tumors","volume":"16","author":"Pedraza-Arevalo","year":"2022","journal-title":"Mol Oncol"},{"issue":"3","key":"2026071419565646300_bnag007-B20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1267\/ahc.12006","article-title":"Expression of somatostatin receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using real-time RT-PCR method and immunohistochemistry","volume":"45","author":"Mizutani","year":"2012","journal-title":"Acta Histochem Cytochem"},{"issue":"46","key":"2026071419565646300_bnag007-B21","doi-asserted-by":"crossref","first-page":"19003","DOI":"10.1073\/pnas.1209590109","article-title":"Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release","volume":"109","author":"Park","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026071419565646300_bnag007-B22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/cells11020267","article-title":"Selective interactions of mouse melanocortin receptor accessory proteins with somatostatin receptors","volume":"11","author":"Wang","year":"2022","journal-title":"Cells"},{"issue":"1","key":"2026071419565646300_bnag007-B23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1475-2867-13-93","article-title":"Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells","volume":"13","author":"Kharmate","year":"2013","journal-title":"Cancer Cell Int"},{"key":"2026071419565646300_bnag007-B24","doi-asserted-by":"crossref","first-page":"892668","DOI":"10.3389\/fendo.2022.892668","article-title":"Dimerization of GPCRs: novel insight into the role of FLNA and SSAs regulating SST(2) and SST(5) homo- and hetero-dimer formation","volume":"13","author":"Treppiedi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026071419565646300_bnag007-B25","doi-asserted-by":"crossref","first-page":"E483","DOI":"10.1152\/ajpendo.00587.2013","article-title":"Porcine sst1 can physically interact with other somatostatin receptors, and its expression is regulated by metabolic\/inflammatory sensors","volume":"306","author":"Gahete","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"2026071419565646300_bnag007-B26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2174\/1566524011313040008","article-title":"Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression","volume":"13","author":"Ruscica","year":"2013","journal-title":"Curr Mol Med"},{"key":"2026071419565646300_bnag007-B27","doi-asserted-by":"crossref","first-page":"111226","DOI":"10.1016\/j.mce.2021.111226","article-title":"The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors","volume":"527","author":"Vitali","year":"2021","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2026071419565646300_bnag007-B28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: from signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front Neuroendocrinol"},{"issue":"4","key":"2026071419565646300_bnag007-B29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7150\/thno.7851","article-title":"PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms","volume":"4","author":"Briest","year":"2014","journal-title":"Theranostics"},{"issue":"7","key":"2026071419565646300_bnag007-B30","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.3390\/ijms25073606","article-title":"The novel SSTR3 agonist ITF2984 exerts antimitotic and proapoptotic effects in human non-functioning pituitary neuroendocrine tumor (NF-PitNET) cells","volume":"25","author":"Di Muro","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026071419565646300_bnag007-B31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1196\/annals.1294.012","article-title":"Molecular signaling of somatostatin receptors","volume":"1014","author":"Lahlou","year":"2004","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"2026071419565646300_bnag007-B32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2265.2002.01619.x","article-title":"Antiangiogenic effects of somatostatin analogues","volume":"57","author":"Garcia de la Torre","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026071419565646300_bnag007-B33","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1210\/en.2002-220949","article-title":"Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities","volume":"144","author":"Florio","year":"2003","journal-title":"Endocrinology"},{"issue":"3","key":"2026071419565646300_bnag007-B34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","article-title":"Pituitary somatostatin receptor signaling","volume":"21","author":"Ben-Shlomo","year":"2010","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2026071419565646300_bnag007-B35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1210\/endrev\/bnae022","article-title":"Structure and function of somatostatin and its receptors in endocrinology","volume":"46","author":"Zhang","year":"2025","journal-title":"Endocr Rev"},{"issue":"9","key":"2026071419565646300_bnag007-B36","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.3390\/cimb46090578","article-title":"Agonists, antagonists and receptors of somatostatin: pathophysiological and therapeutical implications in neoplasias","volume":"46","author":"Periferakis","year":"2024","journal-title":"Curr Issues Mol Biol"},{"issue":"11","key":"2026071419565646300_bnag007-B37","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40618-020-01335-0","article-title":"Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies","volume":"43","author":"Gatto","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2026071419565646300_bnag007-B38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1530\/eje.0.1460701","article-title":"New somatostatin analogs: will they fulfil old promises?","volume":"146","author":"Lamberts","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026071419565646300_bnag007-B39","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"25","key":"2026071419565646300_bnag007-B40","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10446","key":"2026071419565646300_bnag007-B41","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"2026071419565646300_bnag007-B42","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2026071419565646300_bnag007-B43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","article-title":"Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results","volume":"157","author":"Pavel","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"2026071419565646300_bnag007-B44","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2026071419565646300_bnag007-B45","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.eprac.2022.04.009","article-title":"Oral octreotide: a review of recent clinical trials and practical recommendations for its use in the treatment of patients with acromegaly","volume":"28","author":"Yuen","year":"2022","journal-title":"Endocr Pract"},{"key":"2026071419565646300_bnag007-B46","first-page":"P498","article-title":"Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: interim results from a phase 2, randomized, parallel-group study","volume":"99","author":"Chauhan","year":"2024","journal-title":"Endocr Abstr"},{"issue":"1","key":"2026071419565646300_bnag007-B47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13063-023-07834-8","article-title":"Methodology of the SORENTO clinical trial: a prospective, randomised, active- controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET","volume":"25","author":"Singh","year":"2024","journal-title":"Trials"},{"key":"2026071419565646300_bnag007-B48","author":"Bellona"},{"issue":"10","key":"2026071419565646300_bnag007-B49","first-page":"1075","article-title":"Pharmacological characterization of veldoreotide as a somatostatin receptor 4 agonist","volume":"11","author":"Dasgupta","year":"2021","journal-title":"Life (Basel)"},{"issue":"1","key":"2026071419565646300_bnag007-B50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1039\/C6TB02530G","article-title":"AB3-Loaded and tumor-targeted unimolecular micelles for medullary thyroid cancer treatment","volume":"5","author":"Jaskula-Sztul","year":"2017","journal-title":"J Mater Chem B"},{"issue":"3","key":"2026071419565646300_bnag007-B51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2125.1994.tb04344.x","article-title":"Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers","volume":"38","author":"Kuhn","year":"1994","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2026071419565646300_bnag007-B52","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"1-2","key":"2026071419565646300_bnag007-B53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1385\/JMN:18:1-2:15","article-title":"Drug design at peptide receptors: somatostatin receptor ligands","volume":"18","author":"Hannon","year":"2002","journal-title":"J Mol Neurosci"},{"issue":"1","key":"2026071419565646300_bnag007-B54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/cancers16010116","article-title":"The role of receptor-ligand interaction in somatostatin signaling pathways: implications for neuroendocrine tumors","volume":"16","author":"Milewska-Kranc","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1-3","key":"2026071419565646300_bnag007-B55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0014-2999(02)02651-1","article-title":"A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors","volume":"456","author":"Reubi","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2026071419565646300_bnag007-B56","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1210\/me.2009-0321","article-title":"Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways","volume":"24","author":"Cescato","year":"2010","journal-title":"Mol Endocrinol"},{"issue":"28","key":"2026071419565646300_bnag007-B57","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026071419565646300_bnag007-B58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"2026071419565646300_bnag007-B59","doi-asserted-by":"crossref","first-page":"e13423","DOI":"10.1111\/jne.13423","article-title":"European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"issue":"12","key":"2026071419565646300_bnag007-B60","doi-asserted-by":"crossref","first-page":"e13343","DOI":"10.1111\/jne.13343","article-title":"European neuroendocrine tumour society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"2026071419565646300_bnag007-B61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40618-023-02170-9","article-title":"Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story","volume":"47","author":"Faggiano","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026071419565646300_bnag007-B62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000090636","article-title":"Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome","volume":"82","author":"Zomerhuis","year":"2005","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2026071419565646300_bnag007-B63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2026071419565646300_bnag007-B64","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12020-020-02475-2","article-title":"Lanreotide autogel\/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study","volume":"71","author":"Caplin","year":"2021","journal-title":"Endocrine"},{"issue":"8","key":"2026071419565646300_bnag007-B65","doi-asserted-by":"crossref","first-page":"e13318","DOI":"10.1111\/jne.13318","article-title":"European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"2026071419565646300_bnag007-B66","doi-asserted-by":"crossref","first-page":"e13146","DOI":"10.1111\/jne.13146","article-title":"European neuroendocrine tumor society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"2026071419565646300_bnag007-B67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5603\/EP.a2022.0049","article-title":"Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish network of neuroendocrine tumours)","volume":"73","author":"Kos-Kud\u0142a","year":"2022","journal-title":"Endokrynol Pol"},{"issue":"9","key":"2026071419565646300_bnag007-B68","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/jgh.16638","article-title":"Gastrointestinal side effects of somatostatin analogs in neuroendocrine tumors: a focused review","volume":"39","author":"Marasco","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"2026071419565646300_bnag007-B69","doi-asserted-by":"crossref","first-page":"e70062","DOI":"10.1111\/jne.70062","article-title":"Controversies in NEN: an ENETS position statement on nutritional support in neuroendocrine neoplasms","volume":"37","author":"Grozinsky-Glasberg","year":"2025","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"2026071419565646300_bnag007-B70","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s12325-020-01255-8","article-title":"Evaluation of nurse preferences between the lanreotide autogel new syringe and the octreotide long-acting release syringe: an international simulated-use study (PRESTO)","volume":"37","author":"Adelman","year":"2020","journal-title":"Adv Ther"},{"issue":"1","key":"2026071419565646300_bnag007-B71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3803\/EnM.2019.34.1.53","article-title":"Medical treatment with somatostatin analogues in acromegaly: position statement","volume":"34","author":"Chin","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"3","key":"2026071419565646300_bnag007-B72","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12020-022-03227-0","article-title":"Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review","volume":"79","author":"Boguszewski","year":"2023","journal-title":"Endocrine"},{"issue":"2","key":"2026071419565646300_bnag007-B73","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.dld.2020.08.031","article-title":"Update on gastroenteropancreatic neuroendocrine tumors","volume":"53","author":"Andreasi","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"9","key":"2026071419565646300_bnag007-B74","first-page":"749","article-title":"An update on gastroenteropancreatic neuroendocrine tumors","volume":"28","author":"Cives","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"2026071419565646300_bnag007-B75","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1752-0509-1-48","article-title":"Receptor downregulation and desensitization enhance the information processing ability of signalling receptors","volume":"1","author":"Shankaran","year":"2007","journal-title":"BMC Syst Biol"},{"issue":"8","key":"2026071419565646300_bnag007-B76","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1210\/me.2002-0068","article-title":"Brain somatostatin receptors are up-regulated in somatostatin-deficient mice","volume":"16","author":"Ram\u00edrez","year":"2002","journal-title":"Mol Endocrinol"},{"issue":"7","key":"2026071419565646300_bnag007-B77","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1002\/onco.13847","article-title":"Opportunities to improve symptom control with somatostatin congeners in GEP-NETs: a review of key issues","volume":"26","author":"Anthony","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"2026071419565646300_bnag007-B78","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/onco.13633","article-title":"Somatostatin analogs for pancreatic neuroendocrine tumors: any benefit when Ki-67 is \u226510%?","volume":"26","author":"Merola","year":"2021","journal-title":"Oncologist"},{"issue":"10","key":"2026071419565646300_bnag007-B79","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2174\/1389200219666180328113801","article-title":"Pasireotide\u2014mechanism of action and clinical applications","volume":"19","author":"Sawicka-Gutaj","year":"2018","journal-title":"Curr Drug Metab"},{"issue":"6","key":"2026071419565646300_bnag007-B80","doi-asserted-by":"crossref","first-page":"R351","DOI":"10.1530\/ERC-18-0010","article-title":"Pasireotide in the treatment of neuroendocrine tumors: a review of the literature","volume":"25","author":"Vitale","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026071419565646300_bnag007-B81","doi-asserted-by":"crossref","first-page":"106671","DOI":"10.1016\/j.ejps.2023.106671","article-title":"(18)F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of neuroendocrine tumors (NETs)","volume":"193","author":"Gao","year":"2024","journal-title":"Eur J Pharm Sci"},{"issue":"6579","key":"2026071419565646300_bnag007-B82","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/381242a0","article-title":"A cortical neuropeptide with neuronal depressant and sleep-modulating properties","volume":"381","author":"de Lecea","year":"1996","journal-title":"Nature"},{"issue":"1","key":"2026071419565646300_bnag007-B83","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/ijms25010436","article-title":"Somatostatin and somatostatin receptors in tumor biology","volume":"25","author":"Kumar","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026071419565646300_bnag007-B84","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ghir.2017.01.004","article-title":"Cortistatin: a new link between the growth hormone\/prolactin axis, stress, and metabolism","volume":"33","author":"Ib\u00e1\u00f1ez-Costa","year":"2017","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"2026071419565646300_bnag007-B85","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2265.2004.02024.x","article-title":"Distribution pattern of somatostatin and cortistatin mRNA in human central and peripheral tissues","volume":"60","author":"Dam","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2026071419565646300_bnag007-B86","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3390\/pharmaceutics14122785","article-title":"Therapeutic effect of a latent form of cortistatin in experimental inflammatory and fibrotic disorders","volume":"14","author":"Campos-Salinas","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1-2","key":"2026071419565646300_bnag007-B87","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000500812","article-title":"A new generation somatostatin-dopamine analogue exerts potent antitumoral actions on pituitary neuroendocrine tumor cells","volume":"110","author":"V\u00e1zquez-Borrego","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2026071419565646300_bnag007-B88","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1210\/jc.2018-01931","article-title":"Somatostatin receptor expression is associated with metastasis and patient outcome in pulmonary carcinoid tumors","volume":"104","author":"Vesterinen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419565646300_bnag007-B89","first-page":"237","article-title":"Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs","volume":"25","author":"Slaby","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"2026071419565646300_bnag007-B90","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/14728214.2020.1819983","article-title":"Emerging drugs for the treatment of acromegaly","volume":"25","author":"Campana","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"issue":"2","key":"2026071419565646300_bnag007-B91","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrendo.2015.196","article-title":"New therapeutic agents for acromegaly","volume":"12","author":"Melmed","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"2026071419565646300_bnag007-B92","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fendo.2018.00078","article-title":"Novel somatostatin receptor ligands therapies for acromegaly","volume":"9","author":"Paragliola","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026071419565646300_bnag007-B93","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4158\/EP11388.OR","article-title":"A subcutaneous octreotide hydrogel implant for the treatment of acromegaly","volume":"18","author":"Gadelha","year":"2012","journal-title":"Endocr Pract"},{"issue":"10","key":"2026071419565646300_bnag007-B94","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/jc.2013-2262","article-title":"Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly","volume":"98","author":"Chieffo","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565646300_bnag007-B95","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1210\/clinem\/dgaa760","article-title":"Quality of life in patients with neuroendocrine neoplasms: the role of severity, clinical heterogeneity, and resilience","volume":"106","author":"Scandurra","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026071419565646300_bnag007-B96","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s40618-022-01872-w","article-title":"Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study","volume":"45","author":"Modica","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026071419565646300_bnag007-B97","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/00365521.2022.2100228","article-title":"Fatigue and quality of life in patients with neuroendocrine neoplasia","volume":"58","author":"Hummelshoj","year":"2023","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"2026071419565646300_bnag007-B98","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1530\/ERC-20-0066","article-title":"Health-related quality of life in neuroendocrine neoplasia: a critical review","volume":"27","author":"White","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2026071419565646300_bnag007-B99","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0022-3565(25)10638-1","article-title":"Enteral absorption of octreotide: modulation of intestinal permeability by distinct carbohydrates","volume":"274","author":"Fricker","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"2026071419565646300_bnag007-B100","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","article-title":"A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms","volume":"31","author":"Tuvia","year":"2014","journal-title":"Pharm Res"},{"issue":"7","key":"2026071419565646300_bnag007-B101","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565646300_bnag007-B102","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/acsmedchemlett.2c00431","article-title":"Discovery of paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist","volume":"14","author":"Zhao","year":"2023","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2026071419565646300_bnag007-B103","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41467-023-36673-z","article-title":"Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine","volume":"14","author":"Zhao","year":"2023","journal-title":"Nat Commun"},{"issue":"Suppl 1","key":"2026071419565646300_bnag007-B104","doi-asserted-by":"crossref","first-page":"SAT-429","DOI":"10.1210\/js.2019-SAT-429","article-title":"SAT-429 Final results from the first in man phase 1 clinical trial of CRN00808, an orally bioavailable sst2-selective, nonpeptide somatostatin biased agonist, for the treatment of acromegaly: safety, pharmacokinetics, pharmacodynamics, and midazolam drug interaction in healthy volunteers","volume":"3","author":"Madan","year":"2019","journal-title":"J Endocr Soc"},{"issue":"5","key":"2026071419565646300_bnag007-B105","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1210\/clinem\/dgac643","article-title":"ACROBAT edge: safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly","volume":"108","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419565646300_bnag007-B106","author":"ClinicalTrials.gov"},{"issue":"Suppl 1","key":"2026071419565646300_bnag007-B107","doi-asserted-by":"crossref","first-page":"bvae163.1269","DOI":"10.1210\/jendso\/bvae163.1269","article-title":"12531 Long-term safety and efficacy of once-daily oral paltusotine in the treatment of patients with acromegaly: update from acrobat advance","volume":"8","author":"Gadelha","year":"2024","journal-title":"J Endocr Soc"},{"issue":"Suppl 1","key":"2026071419565646300_bnag007-B108","doi-asserted-by":"crossref","first-page":"bvae163.1201","DOI":"10.1210\/jendso\/bvae163.1201","article-title":"12535 efficacy and safety of once-daily oral paltusotine in medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled pathfndr-2 study","volume":"8","author":"Biller","year":"2024","journal-title":"J Endocr Soc"},{"issue":"5","key":"2026071419565646300_bnag007-B109","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1021\/acs.jmedchem.8b02036","article-title":"Discovery of an SSTR2-targeting maytansinoid conjugate (PEN-221) with potent activity in vitro and in vivo","volume":"62","author":"White","year":"2019","journal-title":"J Med Chem"},{"issue":"11","key":"2026071419565646300_bnag007-B110","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/1535-7163.MCT-19-0022","article-title":"Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: a potent and novel therapeutic for the treatment of small cell lung cancer","volume":"18","author":"Whalen","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"15_suppl","key":"2026071419565646300_bnag007-B111","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2018.36.15_suppl.4097","article-title":"First in human phase 1\/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): phase 1 results","volume":"36","author":"Johnson","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026071419565646300_bnag007-B112","author":"Halperin"},{"issue":"15_suppl","key":"2026071419565646300_bnag007-B113","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2021.39.15_suppl.4110","article-title":"The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (Pts) with advanced GI mid-gut neuroendocrine tumor (NET): phase 2 results","volume":"39","author":"Kriksciukaite","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026071419565646300_bnag007-B114","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3390\/molecules28052047","article-title":"Emerging immunotherapeutic and diagnostic modalities in carcinoid tumors","volume":"28","author":"Vellani","year":"2023","journal-title":"Molecules"},{"key":"2026071419565646300_bnag007-B115","author":"El-Rayes"},{"issue":"3","key":"2026071419565646300_bnag007-B116","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2026071419565646300_bnag007-B117","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00280-018-3734-1","article-title":"Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study","volume":"83","author":"Pavel","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2026071419565646300_bnag007-B118","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","article-title":"Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1","volume":"110","author":"Ferone","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419565646300_bnag007-B119","doi-asserted-by":"crossref","first-page":"122173","DOI":"10.1016\/j.lfs.2023.122173","article-title":"Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: from cells to mice","volume":"334","author":"Klomp","year":"2023","journal-title":"Life Sci"},{"issue":"19","key":"2026071419565646300_bnag007-B120","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.18632\/oncotarget.9462","article-title":"Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells","volume":"9","author":"Veenstra","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2026071419565646300_bnag007-B121","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7150\/thno.87345","article-title":"Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments","volume":"14","author":"Richter","year":"2024","journal-title":"Theranostics"},{"issue":"44","key":"2026071419565646300_bnag007-B122","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2026071419565646300_bnag007-B123","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2967\/jnumed.123.265406","article-title":"The emergence of somatostatin antagonist\u2013based theranostics: paving the road toward another success","volume":"64","author":"Imperiale","year":"2023","journal-title":"J Nucl Med"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnag007\/67574462\/bnag007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/47\/4\/496\/67574462\/bnag007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/47\/4\/496\/67574462\/bnag007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:57:17Z","timestamp":1784073437000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/47\/4\/496\/8544663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":123,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,26]]},"published-print":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnag007","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,26]]}}}